Diabetes and cardiovascular risk markers

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes (T2D) is associated with multiple cardiovascular disease (CVD) risk factors, including hyperglycemia, dyslipidemia, and inflammation.
• High rates of CVD mortality and morbidity persist in T2D patients, even with glycemic control.
• Aggressive management of non-glycemic risk factors is crucial for reducing excess CVD risk in T2D.

Purpose of the Study:

• To review cardiovascular risk markers in patients with type 2 diabetes.
• To evaluate the role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in managing CVD risk factors.
• To explore the potential of combined therapies for improving cardiovascular outcomes in T2D.

Main Methods:

• Literature review of MEDLINE and EMBASE databases from 1994 to 2004.
• Analysis of cardiovascular risk markers and their association with insulin resistance.
• Evaluation of the effects of PPARgamma ligands, including thiazolidinediones (TZDs).

Main Results:

• Statin therapy effectively reduces LDL-cholesterol but leaves residual CVD risk.
• PPARgamma ligands (e.g., TZDs) show anti-atherogenic properties, improving HDL cholesterol, triglycerides, and non-lipid risk factors.
• Combining TZDs and statins may offer complementary benefits for CVD risk factor profiles in T2D.

Conclusions:

• Further studies are needed to confirm the value of combined TZD and statin therapy.
• Such approaches may help reduce the excess CVD risk, morbidity, and mortality associated with type 2 diabetes.
• Targeting multiple risk factors, including lipid and non-lipid pathways, is essential for comprehensive CVD management in T2D.